Thursday, December 18, 2008JOHNSON CITY – An international clinical trial study evaluating a drug that may control the progression of Alzheimer’s disease is underway at East Tennessee State University’s James H. Quillen College of Medicine. Approximately 2,050 subjects are expected to enroll at research sites across North America.
“This is an exciting opportunity for local patients living with Alzheimer’s disease,” said Dr. Norman Moore, ETSU professor of Psychiatry and Behavioral Sciences.
“Most current therapies for Alzheimer’s treat the symptoms but not the disease itself. Through clinical trial studies like this, we are poised to discover effective treatment approaches,” added Moore, who also practices with ETSU Physicians and Associates–Psychiatry.
Eligible participants for the study – called ICARA (Investigational Clinical Amyloid Research in Alzheimer’s) – must be between the ages of 50 and 88 and have a diagnosis of mild to moderate Alzheimer’s disease. A caregiver willing to be involved in the study is also necessary. A medical team, including a physician and nurse or study coordinator, will monitor the participants throughout the project.
For more information, contact the ETSU Department of Psychiatry and Behavioral Sciences at (423) 439-7393.